The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes

Cancer

Volumn 103, Issue 7, 2005, Pages 1415-1419

  Berrieman, Helen K ^a   Smith, Laura ^a   O'Kane, Sara L ^a   Campbell, Anne ^b   Lind, Michael J ^a   Cawkwell, Lynn ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bcl 2 family; Immunohistochemistry; Lung carcinoma

Indexed keywords

BIM PROTEIN; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID;

APOPTOSIS; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 15744401627     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20907     Document Type: Article

References (13)

1. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA. 1998;95:4386-4391.
2. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55-64.
3. Gory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Natl Rev Cancer. 2002;2:647-656.
4. Cawkwell L, Gray S, Murgatroyd H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut. 1999;45:409-415.
5. Lai R-S, Wang J-S, Hsu H-K, Chang H-C, Lin C-H, Lin M-H. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn J Clin Oncol. 2002;32:393-397.
6. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol. 2003;29:654-657.
7. Borner MM, Brousset P, Pfanner-Mayer B, et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer. 1999;79:952-958.
8. Cox G, Walker RA, Muller S, Abrams KR, Steward WP, O'Byrne KJ. Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer? Pathol Oncol Res. 2000;6:87-92.
9. Ohmura Y, Aoe M, Andou A, Shimizu N. Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clin Cancer Res. 2000;6:2980-2987.
10. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 2002;33:105-110.
11. Hanaoka T, Nakayama J, Haniuda M, Sato T-A. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in non-small-cell lung cancers. Int J Clin Oncol. 2002;7:152-158.
12. L in resected non-small-cell lung cancers. Histopathology. 2004;44:54-63.
13. Caputi M, Groeger AM, Esposito V, et al. Frequent high expression of Bax pro-apoptotic protein in non-small cell lung cancer. Anticancer Res. 1999;19:825-828.